Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Individualized ibuprofen treatment using serial B-type natriuretic peptide measurement for symptomatic patent ductus arteriosus in very preterm infants

  • Shin, Jeonghee (Department of Pediatrics, Korea University College of Medicine) ;
  • Lee, Eun Hee (Department of Pediatrics, Korea University College of Medicine) ;
  • Lee, Jee Hyun (Department of Pediatrics, Korea University College of Medicine) ;
  • Choi, Byung Min (Department of Pediatrics, Korea University College of Medicine) ;
  • Hong, Young Sook (Department of Pediatrics, Korea University College of Medicine)
  • Received : 2016.11.22
  • Accepted : 2017.04.11
  • Published : 2017.06.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Plasma level of B-type natriuretic peptide (BNP), an emerging, sensitive, and specific biomarker of hemodynamically significant patent ductus arteriosus (PDA), rapidly decreases in infants receiving cyclooxygenase inhibitors for ductal closure. We investigated the usefulness of serial BNP measurement as a guide for individual identification of early constrictive responses to ibuprofen in preterm infants with symptomatic PDA (sPDA). Methods: Before March 2010, the standard course of pharmacological treatment was initiated with indomethacin (or ibuprofen) and routinely followed by 2 additional doses at intervals of 24 hours. After April 2010, individualized pharmacological treatment was used, starting with the first dose of ibuprofen and withholding additional ibuprofen doses if the BNP concentration was <600 pg/mL and clinical symptoms of PDA improved. Results: The BNP-guided group received significantly fewer doses of ibuprofen than the standard group did during the first course of treatment and the entire study period. The need for further doses of cyclooxygenase inhibitors and for surgical ligation was not significantly different between the 2 groups. No significant differences were seen in clinical outcomes and/or complications related to sPDA and/or pharmacological treatment. Conclusion: Individualized BNP-guided pharmacological treatment may be used clinically to avoid unnecessary doses of cyclooxygenase inhibitors without increasing the ductal closure failure and the short-term morbidity related to sPDA.

Keywords

References

  1. Dumas de la Roque E, Fayon M, Babre F, Demarquez JL, Pedespan L. Minimal effective dose of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Biol Neonate 2002;81:91-4. https://doi.org/10.1159/000047190
  2. Su BH, Lin HC, Chiu HY, Hsieh HY, Chen HH, Tsai YC. Comparison of ibuprofen and indometacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2008;93:F94-9.
  3. Carmo KB, Evans N, Paradisis M. Duration of indomethacin treatment of the preterm patent ductus arteriosus as directed by echocardiography. J Pediatr 2009;155:819-22.e1. https://doi.org/10.1016/j.jpeds.2009.06.013
  4. Su BH, Peng CT, Tsai CH. Echocardiographic flow pattern of patent ductus arteriosus: a guide to indomethacin treatment in premature infants. Arch Dis Child Fetal Neonatal Ed 1999;81:F197-200. https://doi.org/10.1136/fn.81.3.F197
  5. Bravo MC, Cabanas F, Riera J, Perez-Fernandez E, Quero J, Perez-Rodriguez J, et al. Randomised controlled clinical trial of standard versus echocardiographically guided ibuprofen treatment for patent ductus arteriosus in preterm infants: a pilot study. J Matern Fetal Neonatal Med 2014;27:904-9. https://doi.org/10.3109/14767058.2013.846312
  6. Choi BM, Lee KH, Eun BL, Yoo KH, Hong YS, Son CS, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005;115:e255-61. https://doi.org/10.1542/peds.2004-1837
  7. Kim JS, Shim EJ. B-type natriuretic Peptide assay for the diagnosis and prognosis of patent ductus arteriosus in preterm infants. Korean Circ J 2012;42:192-6. https://doi.org/10.4070/kcj.2012.42.3.192
  8. Lee JH, Shin JH, Park KH, Rhie YJ, Park MS, Choi BM. Can early B-type natriuretic peptide assays predict symptomatic patent ductus arteriosus in extremely low birth weight infants? Neonatology 2013;103:118-22. https://doi.org/10.1159/000343034
  9. Jeong HA, Shin J, Kim E, Lee EH, Choi BM, Son CS, et al. Correlation of B-type natriuretic peptide levels and echocardiographic parameters in preterm infants with patent ductus arteriosus. Korean J Pediatr 2016;59:183-9. https://doi.org/10.3345/kjp.2016.59.4.183
  10. Kulkarni M, Gokulakrishnan G, Price J, Fernandes CJ, Leeflang M, Pammi M. Diagnosing significant PDA using natriuretic peptides in preterm neonates: a systematic review. Pediatrics 2015;135:e510-25. https://doi.org/10.1542/peds.2014-1995
  11. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723-9. https://doi.org/10.1164/ajrccm.163.7.2011060
  12. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978;92:529-34. https://doi.org/10.1016/S0022-3476(78)80282-0
  13. Kliegman RM, Walsh MC. Neonatal necrotizing enterocolitis: pathogenesis, classification, and spectrum of illness. Curr Probl Pediatr 1987;17:213-88.
  14. Lee EH, Choi BM. Clinical applications of plasma B-type natriuretic peptide assays in preterm infants with patent ductus arteriosus. Neonatal Med 2013;20:323-34. https://doi.org/10.5385/nm.2013.20.3.323
  15. Attridge JT, Kaufman DA, Lim DS. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2009;94:F178-82.

Cited by

  1. Echocardiographic Flow Pattern of Patent Ductus Arteriosus in Preterm Infants with Respiratory Distress: Compared with Other Echocardiographic Parameters vol.29, pp.1, 2017, https://doi.org/10.14734/pn.2018.29.1.27
  2. Diagnosis and Management of Patent Ductus Arteriosus vol.19, pp.7, 2017, https://doi.org/10.1542/neo.19-7-e394
  3. Practice for preterm patent ductus arteriosus; focusing on the hemodynamic significance and the impact on the neonatal outcomes vol.62, pp.7, 2017, https://doi.org/10.3345/kjp.2018.07213
  4. Early Urinary Metabolomics in Patent Ductus Arteriosus Anticipates the Fate: Preliminary Data vol.8, pp.None, 2017, https://doi.org/10.3389/fped.2020.613749
  5. Application of B-Type Natriuretic Peptide in Neonatal Diseases vol.9, pp.None, 2017, https://doi.org/10.3389/fped.2021.767173